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Abstract
 
Dendritic cells (DCs) play a predominant role in activation of natural killer (NK) cells that exert
their functions against pathogen-infected and tumor cells. Here, we used a murine model to investi-
gate the molecular mechanisms responsible for this process. Two soluble molecules produced by
bacterially activated myeloid DCs are required for optimal priming of NK cells. Type I interferons
(IFNs) promote the cytotoxic functions of NK cells. IL-2 is necessary both in vitro and in vivo
for the efficient production of IFN
 
 
 
, which has an important antimetastatic and antibacterial
function. These findings provide new information about the mechanisms that mediate DC–NK
cell interactions and define a novel and fundamental role for IL-2 in innate immunity.
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Introduction
 
After exposure to microbial stimuli, DCs undergo a process
of gene transcription reprogramming that controls an or-
dered sequence of maturation events (1–3) with the sequential
acquisition of specific immune-regulatory activities (4, 5).
These events include an initial profound cytoskeleton rear-
rangement correlated with the loss of antigen internalization
(6), the subsequent enhancement of antigen processing effi-
ciency (7), the loss of T cell tolerization function (8), and
the acquisition of the ability to prime antigen-specific CD4
 
 
 
and CD8
 
 
 
 T cell responses (9). During the maturation pro-
cess, DCs produce cytokines, chemokines, and cell surface
molecules, such as costimulatory molecules, with strictly
defined kinetics (10). Recent studies have focused on the
function of DCs during the early phases of the immune
response, and a predominant role for DCs in activation of
NK cells has been described (11–14).
NK cells are specialized lymphocytes of the innate im-
mune system capable of eliciting responses against patho-
gen-infected and tumor cells. They are activated during the
early phases of an immune response, a few hours after in-
fection. The functions of NK cells are regulated by a balance
of activating and inhibiting signals. These signals are trans-
mitted by inhibitory receptors, which bind class I major
histocompatibility complex (MHC) molecules, and activat-
ing receptors, which bind ligands on tumors and pathogen-
infected cells. Other than surface receptors, cytokines, such
as IL-2, IL-12, IL-18, and type I IFNs, have been shown to
promote NK cell priming (15).
The biological relevance of NK cell activation mediated
by DCs during bacterial infections resides mainly in the
secretion of IFN
 
 
 
 (16), which represents the principal
phagocyte-activating factor (16, 17). With regards to anti-
tumor activities, the interaction between activated DCs and
NK cells has been described to increase the efficiency of
NK cell antitumor effector functions both in vitro and in
vivo in two independent experimental models (14, 18).
Despite the confirmed ability of DCs to prime NK cell
bactericidal and antitumor responses, the molecular mecha-
nisms responsible for DC-mediated NK cell activation remain
to be elucidated.
A classical method to activate NK cells in vitro and to in-
crease their antitumor effectiveness involves culturing NK cells
in the presence of IL-2. However, this cytokine has never
been considered important in vivo for NK cell–mediated anti-
tumor or antimicrobial responses as it was believed that IL-2
was exclusively produced by T cells during the late, anti-
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gen-specific phase of the immune response, when the peak
of NK cell activation was already exhausted (19). On the
other hand, we have observed recently that in the mouse
not only T cells but also DCs are able to produce IL-2 (1).
DCs acquire this capacity 1 h after stimulation with bacteria
(1) or bacterial cell products (20), a timing compatible with
the first signs of in vivo NK cell activation, as defined by the
production of IFN
 
 
 
, after microbial infection (21). Since
DCs can efficiently prime NK cell responses (11–14) and
since this function is more efficient if DCs are infected with
bacteria (16), we hypothesized that, at least in the mouse
system, IL-2 may be a key regulator of DC-dependent NK
cell activation upon bacterial challenge. Our studies investi-
gated the ability of IL-2 secreted by bacterially activated
DCs to regulate NK cell functions.
 
Materials and Methods
 
Mice and Reagents.
 
C57BL/6 and RAG2
 
 
 
/
 
 
 
BALB/c mice
were purchased from Harlan Italy. RAG2
 
 
 
/
 
 
 
C57BL/6 mice
were from Centre de Distribution, de Typage et d’Archivage An-
imal. IL-2
 
 
 
/
 
 
 
C57BL/6 mice were provided by A. Schimpl (Uni-
versity of Würzburg, Würzburg, Germany). All animals were
housed under pathogen-free conditions. For FACS
 
®
 
 analysis and
cell purifications, mAbs were purchased from BD Biosciences.
F(ab
 
 
 
)
 
2
 
 fragments were digested, as described (22), from ascite-
purified anti–IL-2 (S4B6, rat IgG2a) or from total rat IgG
(Bethyl). The IFN
 
 
 
 Duo Elisa kit (R&D Systems) was used to
measure IFN
 
 
 
 in coculture supernatants. Polyclonal antibodies to
mouse IFN
 
 
 
 and IFN
 
 
 
 used to neutralize the bioactivity of type
I IFNs were purchased from PBL Biomedical Laboratories. Nor-
mal rabbit serum was provided by the Animal Care Unit at the
University of Western Australia.
 
BMDCs Preparation.
 
BM cells from C57BL/6 or IL-2
 
 
 
/
 
 
 
C57BL/6 mice were cultured in IMDM (Euroclone) supple-
mented with 2 mM 
 
l
 
-glutamine, 100 U/ml penicillin, 100 
 
 
 
g/
ml streptomycin, 50 
 
 
 
M 2-mercaptoethanol (all from Sigma-
Aldrich), 10% heat-inactivated FBS (IMDM complete medium),
and 10% supernatant of GM-CSF–transduced B16 tumor cells
(23). Fresh medium was added every 2 d. After 7–10 d of culture,
cells were analyzed for CD11c expression and used in assays
when 
 
 
 
90% were CD11c positive.
 
NK Cell Purification.
 
NK cells were enriched by adhesion
from spleens of RAG2
 
 
 
/
 
 
 
 or purified from wild-type mice. For
the enrichment protocol, single cell suspensions were plated in
100-mm tissue culture plates in IMDM complete medium and
incubated for 1 h. Nonadherent cells (
 
 
 
40% DX-5
 
 
 
 cells) were
then recovered and used in appropriate assays. For purification
from wild-type mice, NK cells were positively selected from
splenocytes. 10
 
8
 
 cells were stained with biotinylated anti–pan-NK
cell (DX5) antibody (20 
 
 
 
g/ml) and washed and incubated with
streptavidin MicroBeads (Miltenyi Biotech). Cells were then pos-
itively selected with MS columns, according to the manufac-
turer’s recommendations. NK cells were used when 
 
 
 
95% were
NK1.1 positive.
 
NK–DC Co-cultures.
 
Co-culture experiments were per-
formed with NK cells from both wild-type and RAG2
 
 
 
/
 
 
 
 mice.
wtBMDCs or IL-2
 
 
 
/
 
 
 
BMDCs were resuspended in IMDM
complete medium without antibiotics and plated in 24-well
plates (2.5 
 
 
 
 10
 
5
 
 cells/well). Cells were treated with 
 
Escherichia
coli
 
 DH5
 
 
 
 at a multiplicity of infection (MOI) of 10 for 1.5 h,
washed twice with PBS, and supplemented with IMDM com-
plete medium containing 10% GM-CSF supernatant, 50 
 
 
 
g/ml
gentamycin (Sigma-Aldrich), and 30 
 
 
 
g/ml tetracycline (Sigma-
Aldrich). In some cases, activated BMDCs were cultured with
rIL-2 (3 ng/ml), ascite-purified anti–IL-2, or rat IgG2a isotype
control mAbs (5 
 
 
 
g/ml). After 0.5 h, NK cells (5 
 
 
 
 10
 
5
 
 cells/
well) were added directly to the culture or plated in a transwell
insert, and 18 h later clarified supernatants were tested for IFN
 
 
 
production. For some experiments IL-2
 
 
 
/
 
 
 
BMDCs were plated
in 24-well plates, activated or not with bacteria and after 5 h re-
moved and fixed with glutaraldehyde as described (24). Fixed
cells were resuspended in IMDM complete medium supple-
mented with 10% GM-CSF supernatant, gentamycin, tetracy-
cline, and, where specified, rIL-2 (3 ng/ml).
 
In Vivo Activation of NK Cells.
 
Mice were injected i.v. with
10 
 
 
 
 10
 
6
 
 
 
E. coli
 
 DH5
 
 
 
, and after 4 h spleens were removed and
analyzed for NK cell activation. Single cell suspensions were
prepared and incubated with brefeldin A (10 
 
 
 
g/ml; Sigma-
Aldrich), ionomycin (100 ng/ml; Sigma-Aldrich), and phorbol
12-myristate 13-acetate (50 ng/ml; Sigma-Aldrich) for 3 h. Cells
were fixed with 2% paraformaldehyde, permeabilized with PBS
containing 5% FBS and 0.5% saponin, and stained with FITC-
labeled anti-IFN
 
 
 
 and PE-labeled anti-NK1.1 (PK136) mAbs.
Cells were then analyzed on a FACScan (Becton Dickinson). In
some cases, mice were injected i.p. with F(ab
 
 
 
)
 
2
 
 anti–IL-2 or rat
IgG from day –3 until day 0 (1 mg/day) before bacterial chal-
lenge. Statistical analyses were performed using a two-tailed Stu-
dent’s 
 
t
 
 test.
 
RAG2
 
 
 
/
 
 
 
 Mice Reconstitution.
 
RAG2
 
 
 
/
 
 
 
 mice were recon-
stituted with BMDCs by intraspleen injection of 5 
 
 
 
 10
 
6
 
 wtBMDCs
or IL-2
 
 
 
/
 
 
 
BMDC. After 1 h, mice were injected with 10
 
7
 
 bacte-
ria. To test NK cell activation in vivo, the percentage of IFN
 
 
 
-
positive cells has been evaluated as described previously.
 
Depletion of T Cells.
 
T cells were depleted by i.p. injection of
purified anti-Thy antibody (T24-31.7) 2 d before bacterial infec-
tion. T cell depletion was confirmed by FACS
 
®
 
 analysis of samples
from blood and, after euthanasia, from spleens and lymph nodes.
 
E. coli Clearance.
 
To test the efficiency of bacterial clearance,
spleens were collected 2 h after 
 
E. coli
 
 injection, and unicellular
suspensions were made in 3 ml of PBS. Pellets of single cell sus-
pensions or centrifuged PBS supernatants were then plated on LB
agar (Sigma-Aldrich), and colony-forming units were evaluated
24 h later.
 
B16 Melanoma Challenge.
 
wtBMDCs or IL-2
 
 
 
/
 
 
 
BMDCs
were activated with 
 
E. coli
 
 DH5
 
 
 
 at a MOI of 10 for 1 h, washed
twice with PBS, and incubated 1 h in fresh IMDM complete me-
dium supplemented with 10% GM-CSF supernatant, gentamy-
cin, and tetracycline. BMDCs were then recovered, washed, and
resuspended in PBS. RAG2
 
 
 
/
 
 
 
 mice were injected i.v. with 2 
 
 
 
10
 
6
 
-activated wtBMDCs or IL-2
 
 
 
/
 
 
 
BMDCs and soon after with
B16 melanoma cells (2 
 
 
 
 10
 
5
 
). After 14 d, lungs were removed
and surface metastases were counted. Statistical analyses were per-
formed using a two-tailed Student’s 
 
t
 
 test.
 
Chromium Release Assay for NK Cell Cytotoxicity.
 
NK cells
recovered from DC-NK cocultures were counted to adjust for
viable numbers of NK cells. NK cell cytotoxicity was determined
by standard 
 
51
 
Cr release assay. Briefly, viable NK cells were ti-
trated twofold on 96-well plates, and 
 
51
 
Cr-labeled YAC target
cells (2 
 
 
 
 10
 
3
 
) were added. Each assay was performed in tripli-
cate. After a 4-h incubation at 37
 
 
 
C in 5%CO
 
2
 
, 
 
51
 
Cr release was
measured as described (25). Data are presented as percentage of
specific lysis calculated by the formula: percentage of specific lysis 
 
 
 
(experimental cpm 
 
  
 
spontaneous release cpm)/(total cpm 
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spontaneous release cpm) 
 
 
 
 100. Statistical analyses were per-
formed using a two-tailed Student’s 
 
t
 
 test.
 
Measurement of Type I IFN Activity.
 
The biological activity of
IFN-
 
 
 
/
 
 
 
 was assessed using standard viral protection assays per-
formed on vesicular stomatitis virus (VSV)-infected L929 fibro-
blast cultures as described (26).
 
Results
 
DC-derived IL-2 Is Required In Vitro to Elicit IFN
 
 
 
 Produc-
tion from NK Cells.
 
The ability of wild-type and IL-2–
deficient bone marrow–derived DCs (wtBMDCs, IL-2
 
 
 
/
 
 
 
BMDCs) to induce IFN
 
 
 
 production by syngeneic NK cells
was investigated. wtBMDCs and IL-2
 
 
 
/
 
 
 
BMDCs were acti-
vated with 
 
E
 
. 
 
coli at a MOI of 10, and after 2 h syngeneic
NK cells were added to the DCs. Supernatants were col-
lected 18 h later, and IFN  production was measured.
wtBMDCs were able to induce IFN  production by synge-
neic NK cells (Fig. 1 A), although this function was severely
impaired in IL2 / BMDCs (Fig. 1 A). To verify that IFN 
was produced by NK cells rather than DCs, the presence of
IFN -positive NK cells was confirmed by intracellular stain-
ing of DX5  cells after 4 h of coculture (Fig. 1 A). The in-
ability of IL2 / BMDCs to activate NK cells was not due to
a nonspecific lack of DC function as both wtBMDCs and
IL2 / BMDCs were equally able to interact with NK cells
and induce the up-regulation of the early activation marker
CD69 (unpublished data). In IL2 / BMDCs, defects other
than the ability to produce IL-2 after bacterial stimulation
were excluded. wtBMDCs and IL2 / BMDCs were equiv-
alently activated by bacterial stimulation (as measured by up-
regulation of costimulatory and MHC molecules) and did
not show any difference in viability (1) and in the produc-
tion of various cytokines, including TNF , IL-1 , IL-6, IL-
10, IL-12, and IL-18 (unpublished data). We then analyzed
whether DC-derived IL-2 was also required in an allogeneic
context. Thus, the same coculture experiments were re-
peated, and BALB/c NK cells were incubated with C57BL/6
BMDCs. Again, a deficiency in IL-2 production by DCs
resulted in a lack of NK cell activation (Fig. 1 B). A similar
defect in the capacity of DCs to induce IFN  production by
NK cells was also observed when the effects of the IL-2 se-
creted by bacterially activated wtBMDCs were inhibited
with a blocking anti–IL-2 antibody (Fig. 1 B). Importantly,
exogenous rIL-2 added to DC-NK cocultures restored the
capacity of IL2 / BMDCs to induce IFN  secretion by
both allogeneic and syngeneic NK cells (Fig. 1, A and B).
These observations indicate that, at least in vitro, IL-2 de-
rived from bacterially activated DCs is necessary for DC-
mediated NK cell activation, as measured by their ability to
produce IFN . We could exclude the role of other DC-
derived cytokines, such as IL-12 and IL-18, in NK cell acti-
vation since bacterially activated IL-12– and IL-18–deficient
BMDCs were as efficient as wtBMDCs in inducing IFN 
production by NK cells (unpublished data). Nevertheless,
IL-2 is not the only factor required for this process. When
bacterially activated DCs and NK cells were cultured sepa-
rately in a transwell system, no IFN  secretion by NK cells
was observed (Fig. 1 C), indicating that soluble factors alone
are not sufficient to trigger NK cell activation. Furthermore,
exogenous rIL-2 added to unstimulated wtBMDCs did not
render DCs capable of activating NK cells (Fig. 1 C). These
data suggest that close cell to cell contact between NK cells
and activated DCs is required, together with IL-2, for IFN 
release by NK cells.
DC-derived IL-2 Directly Activates NK Cells. Two pos-
sibilities exist to account for the role of DC-derived IL-2 in
NK cell activation: either IL-2 directly activates NK cells
or it exerts an autocrine activity on DCs, which in turn in-
duces NK cells to secrete IFN . To distinguish between
these two possibilities, we performed the following experi-
Figure 1. DC-derived IL-2 is a key molecule for
DC-mediated NK cell activation in vitro. Immature or
E. coli–activated wtBMDCs and IL-2 / BMDCs were
cultured together with either (A) syngeneic or (B) allo-
geneic NK cells for 18 h. Levels of IFN  in the super-
natant were then quantified by ELISA. The insets in A
represent the intracellular staining performed in the
mixed DC-NK populations after 4 h of coculture. NK
cells were identified as DX5 positive. In B, IL-2 was
also blocked using the S4B6 anti–IL-2 antibody. (C) Cell
contact–dependent activation of NK cells by wtBMDCs.
Unstimulated or E. coli–activated wtBMDCs and allo-
geneic NK cells were cocultured in the same wells or
separated by a porous membrane. NK cells alone were
also cultured in the presence of rIL-2. IFN  in the super-
natant was measured by ELISA after 18 h of coculture.
The experiments were repeated four times with similar
results (A, B, and C). (D) IL-2 produced by activated
DCs directly activates NK cells. Unstimulated or 5-h
bacterially activated IL-2 / BMDCs were fixed and
incubated with allogeneic NK cells. 18 h later, IFN 
was measured in the supernatant by ELISA. The exper-
iment was repeated twice with similar results.NK Cell Priming Induced by Activated Dendritic Cells 290
ment. IL2 / BMDCs were activated by interaction with
bacteria and after 5 h were fixed. rIL-2 was then added to
the fixed IL2 / BMDCs together with unprimed NK
cells. IFN  production by NK cells was tested after 18 h.
Since the IL2 / BMDCs were fixed, the activity of rIL-2
was restricted to an effect exerted directly on NK cells. As
shown in Fig. 1 D, activated and fixed IL2 / BMDCs in-
duced IFN  production from NK cells when supplied with
exogenous rIL-2. In contrast, unstimulated and fixed IL2 / 
BMDCs cultured in the presence of rIL-2 and activated
and fixed IL2 / BMDCs not supplied with rIL-2 did not
induce IFN  release by NK cells. Production of IFN  by
NK cells was also observed after the addition of supernatant
from bacterially activated wtBMDCs to activated and then
fixed IL2 / BMDCs (unpublished data). These data indi-
cate that IL-2 produced by bacterially activated DCs does
not exert an autocrine effect on DCs but rather acts on NK
cells and stimulates the secretion of IFN .
IL-2 Is Required In Vivo to Elicit IFN  Production from NK
Cells. If IL-2 produced by DCs after microbial exposure
is necessary to induce IFN  production by NK cells, IL-2–
deficient mice should show a defect in NK cell activation
in vivo early after bacterial infection. To test this hypothe-
sis, IL-2–deficient mice were injected i.v. with E. coli, and
NK cell activation was analyzed 4 h after infection by mea-
suring the percentage of IFN -positive NK cells in the
spleen. As expected, IL-2–deficient mice infected with
bacteria were unable to mount an early NK cell response
(Fig. 2 A). Similarly, a significant reduction (P   0.05) in
the efficiency of NK cell activation in vivo was observed
by treating wild-type mice with a blocking anti–IL-2 anti-
body before bacterial challenge (Fig. 2 A). These results
demonstrate that in vivo IL-2 is required for effective NK
cell activation after bacterial infection.
IL-2 Required In Vivo to Elicit IFN  Production from NK
Cells Does Not Have a T Cell Origin. To exclude the pos-
sibility that the IL-2 required for NK cell activation had
a T cell origin, T lymphocytes were eliminated in
wtC57BL/6 mice before bacterial challenge as described in
Material and Methods. The efficiency of splenic NK cell
activation 4 h after bacterial infection was then measured.
As shown in Fig. 2 A, at early time points IFN  production
by NK cells after bacterial infection was independent from
the presence of T cells.
We then performed an intracellular staining of spleen
cells to verify if DCs were the principal population produc-
ing IL-2 early after microbial challenge. T and B lympho-
cytes were recognized using antibodies specific for CD19
and TCR , whereas DCs were identified using an anti-
CD11c antibody. Thus, spleen cells were triple stained
with FITC-conjugated anti-CD11c antibody, PE-conju-
gated anti–IL-2 antibody, and biotinylated anti-CD19 and
anti-TCR  antibodies. As shown in Fig. 2 B, the primary
source of IL-2 produced very early after bacterial injection
were CD11c-positive DCs. Together these results strongly
suggest that the IL-2 required in vivo for efficient NK cell
activation is primarily produced by DCs.
DC-derived IL-2 Is Required In Vivo to Elicit IFN  Produc-
tion from NK Cells. To investigate if IL-2 produced by
DCs was required in vivo to elicit IFN  production by NK
cells, we took advantage of RAG2 /  mice. These animals,
other than lacking T and B cells, which could represent
other sources of IL-2, have been shown to develop non-
functional DCs (27). We reasoned that if after bacterial in-
fection in vivo the induction of IFN  production by NK
cell depends on DC activation, these mice should show a
reduced efficiency in this process. As depicted in Fig. 3 A,
in the absence of functional DCs the percentage of IFN -
positive NK cells was indeed strongly reduced after bacte-
rial challenge. Therefore, since RAG2 /  mice do not
have endogenous DCs that can be activated, we were able
to use them as recipients for IL-2–deficient or wtBMDCs
to compare the effectiveness of these cells in inducing NK
cell activation in vivo after bacterial challenge. RAG2 / 
mice were injected in the spleen with wtBMDCs or IL2 / 
BMDCs before bacterial infection, and the percentage of
IFN -positive splenic NK cells was enumerated. As shown
in Fig. 3 B, the efficiency of NK cell activation in RAG2 / 
mice reconstituted with wtBMDCs was similar to that ob-
served in wild-type mice. In contrast, RAG2 /  mice re-
constituted with IL2 / BMDCs showed only a marginal
increase in the percentage of IFN -positive NK cells (Fig.
Figure 2. IL-2 is required in vivo for NK cell activation early after bac-
terial infection. (A) Frequency of IFN –producing NK cells in the spleen
of untreated or E. coli–injected IL-2–deficient or wild-type mice mea-
sured by intracellular cytokine staining. The percentage of IFN -producing
NK cells was also determined in wild-type mice pretreated with anti–IL-2,
anti-Thy1, or isotype control antibodies before bacterial infection. The
experiment was repeated three times with similar results. (B) Triple staining,
3 h after bacterial infection, of spleen cells with FITC-conjugated anti-
CD11c antibody, PE-conjugated anti–IL-2 antibody, and biotinylated
anti-CD19 and anti-TCR  antibodies. In the left panels, the indicated
fractions of IL-2–positive DCs have been calculated as the percentage of
CD11c-positive cells (100%) before and after bacterial infection. Analo-
gously, in right the panels the fraction of IL-2–positive non-DC leukocytes
has been calculated as the percentage of CD19- or TCR -positive cells
(100%) before and after bacterial challenge.Granucci et al. 291
3 B) in comparison to basal percentages (i.e., percentages of
IFN -positive NK cells in RAG2 /  mice infected with
E. coli only). Together these results show that the presence
of functional DCs capable of producing IL-2 is required in
vivo to efficiently induce IFN  production by NK cells.
DC-derived IL-2 Is Required to Elicit Antibacterial and Anti-
tumor NK Cell Responses In Vivo. The functional relevance
of DC-derived IL-2 in activation of NK cell antibacterial and
antitumor responses was then investigated. The role of IFN 
in enhancing the phagocytic activity of macrophages and
other phagocytic cells is well characterized (16, 17). Thus, we
investigated whether the clearance of i.v.-injected bacteria
was different in RAG2 /  mice reconstituted with wtBMDCs
that strongly induce the production of IFN  by NK cells or
with IL2 / BMDCs that are inefficient in activating NK cells
as previously described (Fig. 3 B). For this purpose, 10 mil-
lion E. coli were injected i.v. in DC-treated RAG2 /  mice,
and the bacterial titers in spleens were evaluated 2 h later. At
early time points, the only source of IFN  in vivo are NK
cells as shown in Fig. 4 A. The number of bacteria in the
spleens of mice treated with IL2 / BMDCs was significantly
(P   0.05) higher than that in spleens of mice treated with
wtBMDCs (Fig. 4 B).
In the absence of NKT cells, development of lung me-
tastases after i.v. administration of B16 melanoma cells can
be prevented by activated NK cells (28–30) via the produc-
tion of IFN  (31). Here, we evaluated the level of protec-
tion against the formation of melanoma metastases exerted
by NK cells primed with wild-type or IL-2–deficient DCs
activated by bacterial encounter. B16 tumor cells were in-
jected i.v. into RAG2 /  mice together with E. coli–acti-
vated wtBMDCs or IL2 / BMDCs, and lung metastases
were enumerated after 2 wk. Treatment with bacterially ac-
tivated wtBMDCs significantly (P   0.05) reduced me-
tastasis formation compared with treatment with IL2 / 
BMDCs (Fig. 4 C). The size of the metastases was also very
different in the two experimental conditions. All the me-
tastases that developed in mice treated with IL2 / BMDCs
were visible by naked eye, whereas the metastases that de-
veloped in mice treated with wtBMDCs were not visible
and had to be counted using a dissecting microscope (un-
published data). These observations confirmed the func-
tional relevance of IL-2 produced by bacterially activated
DCs in the activation of NK cells. Our results indicate that
DCs acquire the ability to trigger NK cell–mediated IFN 
responses soon after microbial challenge and that this pro-
cess is mediated by DC-derived IL-2.
Efficient Acquisition of Lytic Function by NK Cells Is Regu-
lated by Type I IFNs Produced by Bacterially Activated Myeloid
DCs. Finally, we investigated whether bacterially activated
DCs were also able to prime NK cell cytotoxicity. NK cells
were cocultured with bacterially activated syngeneic DCs for
24–48 h, and their ability to kill MHC-negative targets was
then measured. E. coli–activated DCs primed NK cell cyto-
toxicity, but unlike regulation of IFN  production cytotox-
icity was not dependent on IL-2. In fact, IL2 / BMDCs
were as efficient as wtBMDCs in inducing NK cell–medi-
ated lysis (Fig. 5 A). In addition, the activation of NK cell
cytolysis was not dependent on DC-derived IL-12 and IL-
18, since after bacterial infection BMDCs from IL-12– and
IL-18–deficient mice induced NK cell cytotoxicity equiva-
lent to that induced by wtBMDCs (unpublished data). NK
cell cytotoxicity and cytokine production can be autono-
mously regulated in response to distinct cytokine-induced
signaling pathways (32). In particular, during viral infections
NK cell cytotoxicity requires STAT1 activation and is prin-
cipally induced by type I IFNs (32). Since myeloid DCs can
produce type I IFNs after viral challenge (33), we tested
Figure 3. IL-2 produced by DCs is required in vivo for NK cell activation.
(A) Frequency of IFN -producing NK cells in the spleen of untreated or
E. coli–injected RAG2 /  or wild-type mice. The experiment was repeated
three times with similar results. (B) Frequency of IFN -positive NK cells
in the spleen of RAG2 /  mice injected intraspleen with wtBMDCs,
IL-2 / BMDCs or not injected (-), and then treated or not with 107
E. coli i.v. Data are means and SDs from four mice analyzed in two inde-
pendent experiments.
Figure 4. DC-derived IL-2 is required in vivo to
elicit antibacterial and antitumor NK cell activity.
(A) Double staining with anti-NK1.1 and anti-IFN 
antibodies of spleen cells from RAG2 /  mice in-
jected (E. coli) or not (untreated) with 107 bacteria.
Before bacterial injection, mice were reconstituted
either with wtBMDCs (wt) or IL2 / BMDCs
(IL2 / ), and the intracellular staining was per-
formed 2 h after bacterial treatment. Percentages of
cells in each quadrant are indicated. (B) Titers of
free bacteria 2 h after i.v. injection of 107 E. coli in
the spleens of wild-type or RAG2 /  mice recon-
stituted with either wtBMDCs or IL2 / BMDCs.
The experiment was repeated twice with similar
results. (C) The number of lung metastases in mice 14 d after i.v. injection of B16 melanoma alone ( ), B16 melanoma and bacterially activated
IL-2 / BMDCs, or B16 melanoma and bacterially activated wtBMDCs. Data represent means and SDs from three independent experiments.NK Cell Priming Induced by Activated Dendritic Cells 292
whether they could also acquire this ability in response to
bacterial encounter. As shown in Fig. 5 B, wtBMDCs pro-
duced type I IFNs upon bacterial challenge. Thus, we inves-
tigated the relevance of these molecules in inducing NK cell
cytotoxicity. Neutralizing the activity of type I IFNs in DC-
NK cocultures resulted in a significant reduction in NK cell
cytotoxicity (Fig. 5 C) (P   0.0001), suggesting that the effi-
cient acquisition of lytic function by NK cells was regulated
by type I IFNs produced by bacterially activated DCs.
Discussion
The cross talk between DCs and NK cells has been de-
scribed in the context of immune responses to infectious
agents and tumors (13, 14, 16, 34). The molecular basis of
these interactions, however, remained largely unrevealed.
Here, we defined some of the DC cytokines that control
the effector functions of NK cells. We showed that IL-2
produced early by bacterially activated mouse DCs plays a
fundamental role in the activation of NK cell–mediated
immunity in vitro and in vivo. This indicates that besides
its well-defined function in acquired immunity, IL-2 is also
necessary, at least after bacterial infections, for the regula-
tion of innate immune responses.
Bacteria and bacterial cell products but not inflammatory
cytokines can induce DCs to produce IL-2 (20). Neverthe-
less, it has been shown that inflammatory cytokines, such as
TNF , may render DCs able to activate NK cells (14).
Therefore, it is possible that in response to diverse physio-
logical stimuli factors other than IL-2 are involved in DC-
NK cross talk.
The specific contribution of IL-2 to the efficient activa-
tion of NK cells described in the present work has been
studied in the mouse system. Our recent studies have shown
that human DCs are also capable of producing IL-2 in an
IL-15–dependent manner (unpublished data). Thus, it re-
mains to be investigated if also in humans IL-2 could play a
role in stimulating NK cells.
IL-12 and IL-18 have been uncontroversially shown to
be involved in NK cell activation (35). Nevertheless, at
least in vitro, we excluded a role of these cytokines in
DC–NK interactions after bacterial encounter, since IL-
12– and IL-18–deficient BMDCs were as efficient as wt-
BMDCs in inducing NK cell activation (unpublished
data). This observation extends previous studies performed
in mouse and human systems in which DC-mediated acti-
vation of NK cells was shown to be independent of IL-12,
IL-18, and also IL-15 (18, 36). In these systems, activation
of NK cells by DCs required cell to cell contact, and sepa-
ration of DC and NK populations in transwells inhibited
NK cell activation. In our system, bacterially activated
DCs need to produce IL-2 but also need to establish cell to
cell contact with NK cells for IFN  release by NK cells to
occur. Thus, IL-2, though necessary, is not sufficient to in-
duce NK cell activation, and additional interactions are re-
quired. These interactions could be necessary either to
concentrate IL-2 locally at the contact site or to allow the
recognition between some surface molecules. The use of
blocking reagents against numerous surface receptors, such
as CD80, CD86, CD154, CD11a, CD50, and Nkp30
failed to reveal a role for these membrane-associated deter-
minants in the productive interaction between DCs and
NK cells (12, 16). Here, we tested the possible relevance
of other surface molecules, and we excluded the involve-
ment of NKG2D, ICOSL, and CX3CR1 (unpublished
data) in NK cell activation mediated by bacterially acti-
vated DCs.
Since DCs express functional IL-2 receptors and up-reg-
ulate the IL-2R  subunit after activation, the possibility
existed that IL-2 exerted its function on DCs in an auto-
crine manner by contributing to the DC maturation pro-
cess. This hypothesis was dismissed by our findings that IL-2
is directly required for NK cell activation. Moreover, no
clear IL-2 effect on DC maturation measured by up-regu-
lation of costimulatory or MHC molecules and acquisition
Figure 5. NK cell cytotoxicity is regulated by DC-derived type I IFNs.
(A) DC-derived IL-2 is not required for the induction of NK cell cytotox-
icity. Untreated or E. coli–activated wtBMDCs and IL-2 / BMDCs were
cocultured with syngeneic NK cells for 48 h. NK cell cytotoxicity pre-
sented as the percentage of lysis of YAC targets was measured by a standard
51Cr release assay. (B) Bacterially activated BMDCs secrete type I IFNs.
The amount of IFN   in the supernatant of wtBMDCs and NK cell cul-
tures was measured after exposure to E. coli by a standard viral protection
assay. (C) Type I IFNs control the induction of NK cell cytotoxicity after
bacterial infection. Untreated or E. coli–activated wtBMDCs were cocul-
tured with syngeneic NK cells for 24 h in the presence or absence of IFN  -
blocking antibodies (P   0.0001 when the percentage of lysis is compared
between wtBMDC   E. coli   NK   isotype and wtBMDC   E. coli  
NK   anti-IFN   at an E:T ratio of 7.5:1). The data are representative of
three independent experiments conducted with triplicate samples.Granucci et al. 293
of T cell priming capacity was observed in our studies (un-
published data).
Residual DC-dependent NK cell activity can be induced
in vivo in the absence of IL-2, a phenomenon not observed
in our in vitro assays. Previous in vitro studies have shown
that DCs may acquire the capacity to induce NK cell–
mediated IFN  secretion independently of microbial infec-
tion and IL-2 production (13) provided they are exposed to
IL-4 (14, 37). It is possible that the residual NK activation
observed in vivo in the absence of IL-2 is due to an alterna-
tive mechanism of DC conditioning, possibly involving IL-4.
Moreover, we cannot exclude the possibility that in bacte-
rial infections cytokines such as IL-15 may represent addi-
tional factors required for DC-dependent NK cell activa-
tion in vivo. Since bacterially activated DCs produce type I
IFNs, a role for IL-15 is particularly attractive as this cyto-
kine has been shown to be produced by DCs in response to
type I IFNs (38).
The involvement of NK cells in antitumor responses
has been observed in different experimental systems (39).
Moreover, in patients with cancer NK cell activities have
been shown to be impaired as assessed by the reduced func-
tionality of NK cells from patients ex vivo. In agreement
with these observations, apparently disease-free patients
with functional peripheral blood NK cells have a signifi-
cantly longer metastasis-free survival time than those with
low NK cell activity (15). Antitumor NK cell functionality
is strongly increased after activation (39). The ability of
bacterially primed DCs to induce antitumor NK cell activ-
ities may explain the efficacy of bacterially based immune
therapies (40, 41), and studies presented in this paper pro-
vide important clues as to how DCs may prime NK cell–
mediated antitumor functions. Indeed, in our mouse sys-
tem the antimetastatic effects of NK cells are dependent on
the IL-2 released by bacterially activated DCs. Independent
studies analyzing two different tumor models in vivo re-
ported that NK cell activation is independent of IL-12 and
IL-15 (18, 36). At least for IL-12, the reported observations
are in agreement with our in vitro experiments in which
DC-mediated activation of NK cell cytotoxic and secretory
functions did not depend on this cytokine.
Bacterially activated DCs elicit NK cell cytotoxicity in
an IL-2–independent manner. This is somehow surprising
since NK cells exposed for long periods to high doses of sol-
uble IL-2 acquire both secretory and cytotoxic activities.
However, NK cell cytotoxicity and cytokine production
are independently activated and involve distinct cytokine-
induced signaling pathways (32). Although activation of
STAT4 is critical for IFN  production by NK cells, the ac-
quisition of cytotoxic function requires STAT1 signaling
(32). Although IL-2 is able to activate the STAT1, STAT4,
and STAT5 signaling pathways in NK cells in vitro (42), IL-
2–mediated STAT1 activation is inefficient (43). Usually,
the IL-2 doses to which NK cells are exposed in vitro to in-
duce activation are extremely high and possibly sufficient to
efficiently activate the STAT1 pathway and thus induce NK
cell cytotoxicity. In contrast, the IL-2 amounts to which
NK cells are exposed in the cocultures with bacterially acti-
vated DCs are low and thus presumably not sufficient to in-
duce effective activation of the STAT1 pathway.
Activation of STAT1 in NK cells has been described to
be predominantly mediated by type I IFNs (32). It has been
shown recently that type I IFNs can be produced not only
by plasmacytoid DCs but also by myeloid DCs exposed to
viruses or viral products (33). In this study, we found that
myeloid DCs derived in vitro from BM precursors can pro-
duce type I IFNs after bacterial activation. The precise
contribution of myeloid and plasmacytoid DCs in the pro-
duction of type I IFNs in different physiological circum-
stances in vivo remains to be defined. Our results suggest
that production of type I IFNs may represent a poorly rec-
ognized response of myeloid DCs to several infectious
agents, including bacteria.
The up-regulation of NK cell cytotoxicity by bacterially
activated DCs may not be directly required for their anti-
bacterial effects. The biological relevance of this response
may relate to the fact that cytotoxicity could contribute to
controlling the late phases of the immune response by limit-
ing inflammation and restoring homeostatic balance after in-
fection (16, 37). DCs are susceptible to NK cell–mediated
lysis, hence the ability to elicit NK cell cytotoxicity may be
a means for DCs to limit their own activity. Furthermore,
we would like to propose that, given the ability of NK cells
to acquire strong cytolytic function after interaction with
bacterially activated DCs, bacterial infections may contrib-
ute to maintaining a basal level of alert against tumors.
Our findings reveal novel aspects of the molecular
mechanisms that contribute to DC–NK interactions both
in vitro and in vivo and define an new role for IL-2 in in-
nate immunity. Understanding the regulation of innate im-
mune responses and defining the critical mediators places us
closer to effectively manipulate these responses to improve
therapeutic outcomes.
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